The effect of topiramate in improvement of migraineur's clinical status; a clinical trial

Several studies suggest improvements in quality of life in migraine patients with topiramate. MIDAS (Migraine Disability Assessment) and HIT6 (Headache Impact Test) are two questionnaires for evaluating migraine severity. The aim of this study was to assess the efficacy of Topiramate 100 mg/day in control and prophylaxis of migraine headache. Eighty-nine patients who suffered from migraine headaches according to International Headache Society criteria were enrolled. Topiramate 25 mg/d was prescribed for them in the first week and was increased 25 mg/d weekly (up to 100 mg/d) and the maximum dose continued for 3 months. The HIT6 and MIDAS tests were done before and after intervention. Results The frequency and severity of migraine headache reduced significantly after 3 months of Topiramate 100 mg/d. The HIT6 score before and after intervention was 63.3± 5.4 and 51.11± 8.9 and the difference was significant (P < 0.0001). The MIDAS score before and after intervention was 25± 21.4 and 9.7± 15 and this difference was significant (P < 0.0001). The prescription of Topiramate 100 mg/ day in two divided dose can reduce the severity and frequency of migraine headache.